2BB score and signals
Denali Therapeutics Inc.’s current 2BB score is 47 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 60 | Moderate |
| Momentum | 50 | Stable |
| Financial strength | 27 | Weak |
| Quality | 100 | Very Strong |
| Risk | 39 | Low |
Company facts
| Headquarters | South San Francisco, California, United States |
| Founded | 2013 |
| Employees | 507 |
| 52-week range | $12.58 – $27.30 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-24 | — | -0.6406 | — | $24.43M |
| 2026-11-04 | — | -0.5163 | — | $11.08M |
| 2026-08-06 | — | -0.6699 | — | $14.91M |
| 2026-05-07 | -0.69 | -0.7405 | $0.00 | $784,614.00 |
Related companies
